SCHEMBL16845386

SCHEMBL16845386

CCc1ccc(F)cc1NC(=O)[C@H]1[C@H](c2ccc(S(N)(=O)=O)cc2)C1(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC9A1 P19634 2/20 0.42
▸ CNR1 P21554 1/20 0.41
▸ CA1 P00915 8/20 0.40
▸ CA2 P00918 8/20 0.40
▸ CA9 Q16790 8/20 0.40
▸ CA12 O43570 7/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CHRNA7 P36544 2/20 0.39
▸ CA7 P43166 3/20 0.38
▸ CA4 P22748 2/20 0.38
▸ SOS1 Q07889 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16820016 1.00 SLC9A1 (0.42) SLC9A1CNR1CA1CA2CA9
SCHEMBL18938279 1.00 SLC9A1 (0.42) SLC9A1CNR1CA1CA2CA9
SCHEMBL16819981 0.87 POLB (0.43) SLC9A1CA1CA2CA9CA12
SCHEMBL16819942 0.87 POLB (0.43) SLC9A1CA1CA2CA9CA12
SCHEMBL20707890 0.86 SLC9A1 (0.43) SLC9A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL16819950 0.85 CA2 (0.44) SLC9A1CA1CA2CA9CA12
SCHEMBL16845421 0.85 HTT (0.55) SLC9A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL16819959 0.85 HTT (0.55) SLC9A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL16845528 0.84 MAPT (0.45) CA1CA2CA9CA12HTT
SCHEMBL16819899 0.84 MAPT (0.45) CA1CA2CA9CA12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888229-B1 alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF MERCK SHARP & DOHME (US) 2019-02-06 — — EP disclosed
US-9790173-B2 Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I MERCK SHARP & DOHME CORP. (US) 2017-10-17 — — US disclosed
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I MERCK SHARP & DOHME CORP. (US) 2017-06-08 — — US disclosed
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I MERCK SHARP & DOHME CORP. 2015-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I CHRNA7, CHRNA5, CHRNA6 SLC9A1 1860/4885CNR1 63/4885CA1 1704/4885
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I CHRNA7, CHRNA6, CHRNA5 SLC9A1 2670/4885CNR1 73/4885CA1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback